- Home
- LIEN vs ACRV Comparison
LIEN vs ACRV Comparison
Compare LIEN & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- ACRV
- Stock Information
- Founded
- LIEN 2021
- ACRV 2018
- Country
- LIEN United States
- ACRV United States
- Employees
- LIEN N/A
- ACRV N/A
- Industry
- LIEN
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- LIEN
- ACRV Health Care
- Exchange
- LIEN NYSE
- ACRV Nasdaq
- Market Cap
- LIEN 294.4M
- ACRV 243.8M
- IPO Year
- LIEN 2022
- ACRV 2022
- Fundamental
- Price
- LIEN $13.00
- ACRV $8.03
- Analyst Decision
- LIEN
- ACRV Strong Buy
- Analyst Count
- LIEN 0
- ACRV 5
- Target Price
- LIEN N/A
- ACRV $22.60
- AVG Volume (30 Days)
- LIEN 22.8K
- ACRV 76.9K
- Earning Date
- LIEN 11-08-2024
- ACRV 11-07-2024
- Dividend Yield
- LIEN 7.71%
- ACRV N/A
- EPS Growth
- LIEN 5.69
- ACRV N/A
- EPS
- LIEN 0.90
- ACRV N/A
- Revenue
- LIEN $12,422,942.00
- ACRV N/A
- Revenue This Year
- LIEN N/A
- ACRV N/A
- Revenue Next Year
- LIEN N/A
- ACRV N/A
- P/E Ratio
- LIEN $14.43
- ACRV N/A
- Revenue Growth
- LIEN 44.81
- ACRV N/A
- 52 Week Low
- LIEN $7.29
- ACRV $3.19
- 52 Week High
- LIEN $13.38
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- ACRV 58.49
- Support Level
- LIEN N/A
- ACRV $7.58
- Resistance Level
- LIEN N/A
- ACRV $8.36
- Average True Range (ATR)
- LIEN 0.00
- ACRV 0.33
- MACD
- LIEN 0.00
- ACRV 0.15
- Stochastic Oscillator
- LIEN 0.00
- ACRV 78.15
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company's investment objective is to maximize risk-adjusted returns on equity for its stockholders by investing primarily in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.